DanDi Bioscience

http://m.biospectator.com/view/news_view.php?varAtcId=10260

This post has been translated from the original article dated 4/23/2020. 

Dandi Bioscience will be listed on the KONEX market on the 24th. Dandibio, a subsidiary of Next Science, announced on the 23rd that it recently received approval from the Korea Exchange for a new listing of KONEX. However, sales and trading in the KONEX market will begin the next day, the 24th. Dandibio is a biotech established in 2016 by Park Young-min, a professor at Konkuk University's Graduate School of Medicine, and is speeding up the development of new drugs, focusing on two key pipelines: sepsis treatment and immuno-cancer drugs. The two pipelines are currently in the non-clinical stage, and the treatment for double sepsis aims to enter phase 1 clinical trial in the United States in 2021. Sepsis is a fatal disease with a mortality rate of 30%, and there is no suitable treatment so far. Starting from the long-standing research results of CEO Park, an authority on immunology, sepsis treatment has a dual function that not only directly removes bacteria but also binds to endotoxins secreted during bacterial destruction to control organ failure caused by cytokine storms. Another pipeline, immuno-cancer drugs, greatly improves the limited immune-inducing response of existing anticancer vaccines or immuno-enhancing drugs, changing the immune suppression or resistance environment in the tumor, inducing immune mechanisms to attack tumor cells. In particular, by combining the drug delivery platform developed independently, it is expected to have a synergistic effect in combination with immune checkpoint inhibitors in terms of efficacy. An official from Dandibio said, "We will build HBS (HLB Bio-System) with Next Science, the largest shareholder, HLB and HLB Life Sciences, which have global clinical experience, and Immunomic Theraputics of the United States to seek growth through organic cooperation between companies."